Share:

Rituximab (trade names Rituxan and MabThera) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab destroys B cells, and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

Rituxan

Tiny Biotech Developing Drugs Akin To Biogen’s Rituxan Seen As Potential …
Forbes
One small biopharmaceutical that believes it has a proven technology for another blockbuster is TG Therapeutics (TGTX), which is focused on developing drugs for the treatment of cancer and other underserved therapeutic needs, including hematologic …read all

http://www.forbes.com/sites/genemarcial/2013/05/27/tiny-biotech-developing-drugs-akin-to-biogens-rituxan-seen-as-potential-buyout-bet/

Tweet